Zadnji put ažurirano :
03/05/2024
Lijek protiv karcinoma   Fludarabine phosphate  
Injekcija
Stabilizacija rješenja Stabilnost mješavine Stabilizacijski faktor Kompatibilnosti Način davanja lijeka Bibliografija Pdf
   Kemijska struktura  

Nekomercijalni   Nekomercijalni     

Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima

Acetaflur Meksiko
Asoleudox Meksiko
Beneflur Meksiko, Španjolska
Fludabin Peru
Fludacel Indija, Peru
Fludakebir Peru
Fludalym Turska
Fludara Indija, Austrija, Belgija, Čile, Danska, Egipat, Finska, Francuska, Iran, Irska, Italija, Kolumbija, Luksemburg, Madžarska, Malezija, Nizozemska, Njemačka, Novi Zeland, Poljska, Portugal, Rumunjska, S A D, Saudijska Arabija, Švedska, Švicarska, Velika Britanija, Venecuela
Fludarabin Island, Italija, Norveška, Švedska, Švicarska
Fludarabina Argentina, Kolumbija, Peru, Rumunjska, Španjolska
Fludarabine Belgija, Iran, Kanada, Norveška, Novi Zeland, S A D, Švicarska
Fludarin Indija
Fludarosa Argentina
Forclina Peru
Ludabina Čile, Kolumbija
Mepredin Peru
Naprobin Indija
Neoflubin Iran
Bibliografija   Injekcija   Bibliografija : Fludarabine phosphate  
Vrsta Publikacija
3 Časopis Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 Časopis Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Časopis Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Časopis Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Časopis Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Časopis Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Časopis Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Časopis Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 Časopis Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
492 Časopis Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 Časopis Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1410 Časopis Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 Časopis Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
2344 Laboratorija Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009
3306 Časopis Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2.
3595 Laboratorija Aciclovir - Summary of Product Characteristics
Hospira 2009
3604 Laboratorija Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012
3637 Laboratorija Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014
3644 Laboratorija Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3670 Časopis Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3838 Laboratorija Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
4398 Časopis Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020

  Mentions Légales